Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 Metastatic Breast Cancer Patients: a Turkish Oncology Group (Tog) Study
| dc.authorid | Turan, Merve/0000-0003-4021-6095 | |
| dc.authorid | Tanriverdi, Ozgur/0000-0002-0598-7284 | |
| dc.authorid | Turker, Sema/0000-0001-9040-7266 | |
| dc.authorid | Uslu, Ruchan/0000-0002-9584-6134 | |
| dc.authorid | Erdem, Dilek/0000-0001-6495-6712 | |
| dc.authorid | Beypinar, Ismail/0000-0002-0853-4096 | |
| dc.authorscopusid | 6603166584 | |
| dc.authorscopusid | 7006287366 | |
| dc.authorscopusid | 56304997100 | |
| dc.authorscopusid | 57387529400 | |
| dc.authorscopusid | 24829581300 | |
| dc.authorscopusid | 57204682729 | |
| dc.authorscopusid | 6603597966 | |
| dc.authorwosid | Uysal, Mukremin/B-8956-2014 | |
| dc.authorwosid | Menekşe, Serkan/Hnp-3265-2023 | |
| dc.authorwosid | Tanriverdi, Ozgur/M-2172-2015 | |
| dc.authorwosid | Paydas, Semra/F-3132-2018 | |
| dc.authorwosid | Degirmenci, Mustafa/Lce-4086-2024 | |
| dc.authorwosid | Dogan, Mutlu/Gnp-7311-2022 | |
| dc.authorwosid | Beypinar, Ismail/Aan-1107-2020 | |
| dc.contributor.author | Bilici, Ahmet | |
| dc.contributor.author | Uysal, Mukremin | |
| dc.contributor.author | Menekse, Serkan | |
| dc.contributor.author | Akin, Semih | |
| dc.contributor.author | Yildiz, Fatih | |
| dc.contributor.author | Turan, Merve | |
| dc.contributor.author | Turhal, Serdar | |
| dc.date.accessioned | 2025-05-10T17:13:38Z | |
| dc.date.available | 2025-05-10T17:13:38Z | |
| dc.date.issued | 2022 | |
| dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
| dc.department-temp | [Bilici, Ahmet; Olmez, Omer Fatih; Acikgoz, Ozgur] Medipol Univ, Med Fac, Dept Med Oncol, TEM Avrupa Otoyolu Goztepe Cikisi 1, Bagcilar, Turkey; [Uysal, Mukremin; Beypinar, Ismail] Afyon Kocatepe Univ, Med Fac, Dept Med Oncol, Afyon, Turkey; [Menekse, Serkan] Manisa State Hosp, Dept Med Oncol, Manisa, Turkey; [Akin, Semih; Uslu, Ruchan] Ege Univ, Med Fac, Dept Med Oncol, Izmir, Turkey; [Yildiz, Fatih] Dr Abdurrahman Yurtarslan Oncol Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey; [Turan, Merve] Adnan Menderes Univ, Med Fac, Dept Med Oncol, Aydin, Turkey; [Sezgin Goksu, Sema] Akdeniz Univ, Med Fac, Dept Med Oncol, Antalya, Turkey; [Sakalar, Teoman] Erciyes Univ, Med Fac, Dept Med Oncol, Kayseri, Turkey; [Degirmenci, Mustafa] Izmir Tepecik Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey; [Erdem, Dilek] Bahcesehir Univ, Med Fac, Dept Med Oncol, Samsun, Turkey; [Basaran, Gul; Demir, Atakan] Acibadem Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey; [Avci, Nilufer] Medicana Bursa Hosp, Dept Med Oncol, Bursa, Turkey; [Tural, Deniz] Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey; [Sakin, Abdullah] Yuzuncu Yil Univ, Med Fac, Dept Med Oncol, Van, Turkey; [Turker, Sema] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey; [Temiz, Suleyman] Kocaeli Acibadem Hosp, Dept Med Oncol, Kocaeli, Turkey; [Kaplan, Muhammed Ali] Dicle Univ, Med Fac, Dept Med Oncol, Diyarbakir, Turkey; [Dogan, Mutlu] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey; [Bilgetekin, Irem] Gazi Univ, Med Fac, Dept Med Oncol, Gazi, Turkey; [Tanriverdi, Ozgur; Bilgetekin, Irem] Mugla Sitki Kocman Univ, Med Fac, Dept Med Oncol, Mugla, Turkey; [Cinkir, Havva Yesil] Gaziantep Univ, Med Fac, Dept Med Oncol, Gaziantep, Turkey; [Paydas, Semra] Cukurova Univ, Med Fac, Dept Med Oncol, Adana, Turkey; [Turhal, Serdar] Anadolu Med Ctr, Dept Med Oncol, Istanbul, Turkey | en_US |
| dc.description | Turan, Merve/0000-0003-4021-6095; Tanriverdi, Ozgur/0000-0002-0598-7284; Turker, Sema/0000-0001-9040-7266; Uslu, Ruchan/0000-0002-9584-6134; Erdem, Dilek/0000-0001-6495-6712; Beypinar, Ismail/0000-0002-0853-4096 | en_US |
| dc.description.abstract | Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients. | en_US |
| dc.description.woscitationindex | Science Citation Index Expanded | |
| dc.identifier.doi | 10.1080/07357907.2021.2017952 | |
| dc.identifier.endpage | 209 | en_US |
| dc.identifier.issn | 0735-7907 | |
| dc.identifier.issn | 1532-4192 | |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.pmid | 34894960 | |
| dc.identifier.scopus | 2-s2.0-85121803055 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.startpage | 199 | en_US |
| dc.identifier.uri | https://doi.org/10.1080/07357907.2021.2017952 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14720/8257 | |
| dc.identifier.volume | 40 | en_US |
| dc.identifier.wos | WOS:000734258300001 | |
| dc.identifier.wosquality | Q4 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis inc | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Everolimus | en_US |
| dc.subject | Exemestane | en_US |
| dc.subject | Metastatic Breast Cancer | en_US |
| dc.subject | Hormone Receptor-Positive | en_US |
| dc.subject | Her - Negative | en_US |
| dc.subject | Efficacy | en_US |
| dc.title | Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 Metastatic Breast Cancer Patients: a Turkish Oncology Group (Tog) Study | en_US |
| dc.type | Article | en_US |